Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 4/20 | 0.52 |
| ▸ | HTR1D | P28221 | 7/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109812 | 0.84 | HTR2C (0.47) | HTR2CHTR2AHTR1DEGFR | |
| SCHEMBL30403505 | 0.80 | HTR2C (0.57) | HTR2CHTR2AHTR1DEGFRHTR6 | |
| SCHEMBL24109831 | 0.80 | HTR2C (0.57) | HTR2CHTR2AHTR1DEGFRHTR6 | |
| SCHEMBL24824870 | 0.80 | HTR2C (0.36) | HTR2CHTR2A | |
| SCHEMBL24110604 | 0.76 | HTR2C (0.47) | HTR2CHTR2AHTR1DEGFR | |
| SCHEMBL23956081 | 0.74 | HTR2A (0.69) | HTR2CHTR2AHTR1DEGFRHTR6 | |
| SCHEMBL23956101 | 0.74 | HTR2C (0.60) | HTR2CHTR2AHTR1DEGFRHTR6 | |
| SCHEMBL3892738 | 0.74 | HTR2A (0.57) | HTR2CHTR2AHTR1DHTR6HTR7 | |
| SCHEMBL18227699 | 0.72 | HTR2C (0.46) | HTR2CHTR2AHTR1DEGFRHTR6 | |
| SCHEMBL23956080 | 0.71 | HTR2C (0.69) | HTR2CHTR2AHTR1DHTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021252692-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219969-A1 | ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF | GAP43, SLC18A2, PNMT | HTR2C 35/4885HTR2A 10/4885HTR1D 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.